Skip to main content

Table 1 Patient characteristics at first clinical ISR presentation

From: In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario

ParameterTotal (n = 191)ACS cohort (n = 118)Non-ACS cohort (n = 73)P value
Demographics
 Age61 ± 1062 ± 1059 ± 100.074
 Men155 (81.2%)90 (76.3%)65 (89.0%)0.036
 BMI23.5 ± 3.523.7 ± 3.923.1 ± 2.70.479
Clinical characteristics
 Diabetes109 (57.1%)68 (57.6%)41 (56.2%)0.881
 Hypertensionƚ104 (54.5%)66 (55.9%)38 (52.1%)0.655
 Chronic kidney disease21 (11.0%)18 (15.3%)3 (4.1%)0.017
 Acute kidney injury32 (16.8%)24 (20.3%)8 (11.0%)0.112
 Dyslipidemia*98 (67.1%)55 (63.2%)43 (72.9%)0.282
 Current tobacco use39 (20.4%)22 (18.6%)17 (23.3%)0.464
 CCF34 (17.8%)30 (25.4%)4 (5.5%)< 0.001
 NYHA 3,420 (10.5%)14 (11.9%)6 (8.2%)0.476
 LVEF53 ± 1151 ± 1054 ± 110.076
 Previous MI100 (52.4%)65 (55.1%)35 (47.9%)0.373
 Previous CABG14 (7.3%)9 (7.6%)5 (6.8%)1.000
 Statin therapy163 (85.3%)99 (83.9%)64 (87.7%)0.533
Lipid profile* (mg/dL)
 Total cholesterol145 ± 42146 ± 45144 ± 370.785
 LDL80 ± 3580 ± 3879 ± 310.896
 HDL39 ± 1241 ± 1338 ± 100.126
 Triglycerides130 ± 71124 ± 67140 ± 760.166
  1. ACS acute coronary syndrome, BMI body mass index, CABG coronary artery bypass grafting, CCF congestive cardiac failure, LVEF left ventricular ejection fraction, LDL low-density lipoprotein, HDL high-density lipoprotein, MI myocardial infarction, NYHA New York Heart Association
  2. *Dyslipidemia defined as total cholesterol > 250 mg/dL, LDL cholesterol > 130 mg/dL, HDL cholesterol < 40 mg/dL (< 50 mg/dL for women) in the fasting state. Data available for 146 patients
  3. ƚBlood pressure > 140/90 mmHg or the use of antihypertensive therapy